Objective: Protection from ischaemic preconditioning (IP) is dependent on activation of protein kinase C (PKC), and preconditionings protection can be mimicked by stimulation of various membrane receptors which are known to activate PKC. It is well known that K, channel activation is cardioprotective. We tested the hypothesis that preischaemic treatment with endothelin-1 (ET-l) can protect against infarction by a PKC-dependent mechanism and by activating K, channels. Methods: Buffer-perfused isolated rat hearts were subjected to 30 min regional ischaemia and 120 min reperfusion. Risk zone was determined by fluorescent particles, and infarct size by TX staining. Results: Treatment with ET-1 in a dose of 1 nM prior to ischaemia significantly reduced infarct size in % of the risk zone compared to the control group (infarct size: 14
Introduction
Endothelin-1, a potent vasoconstrictor, was first described in 1988 [l] . In recent years a large number of studies have been published proposing that endothelin participates in mediating ischaemia-reperfusion injury in the heart [2] . Intracoronary infusion of endothelin can lead to myocardial ischaemia [3] , and the vasoconstrictor potency of endothelin is reported to be substantially increased in the postischaemic myocardium [4, 5] . In humans undergoing myocardial infarction increased plasma concentrations of endothelin-1 have been reported [6] . Increased amounts of endothelin are released after ischaemia from pig [7] , dog [8] and rabbit [9] hearts in vivo and from isolated rat hearts [4] . Very recently de novo synthesis of endothelin-1 by cardiomyocytes subjected to ischaemia has also been demonstrated [ 101. In rat [l 11 and rabbit [9] a monoclonal antibody against endothelin-1 reduced infarct size after myocardial ischaemia and reperfusion, thus supporting the theory that endothelin-1 might contribute to ischaemia-reperfusion injury. Likewise, in pig [12] and rat [13] hearts in vivo nonselective blockers of endothelin A (ET, ) and B (ET,) receptors have been reported to reduce infarct size, and in dog intracoronary infusion of the selective ET, receptor antagonist, BQ-123, has also been reported to reduce myocardial infarct size [ 141.
However, in several other studies this protective effect of endothelin receptor blockade during ischaemia and reperfusion has not been demonstrated. Richard et al. [15] reported that, in the anaesthetized rat, the nonselective ETA/ET, receptor blocker, bosentan, did not influence myocardial infarct size. Also, in dog intravenous infusion of the ET, selective receptor antagonist, BQ-123, did not reduce infarct size [16] , and in the anaesthetized rabbit the ET, selective receptor antagonist, FR-139317, did not protect against infarction [17] . In one study in the anaesthetized dog, FR-139317 actually increased infarct size, and the authors suggested that endogenous endothelin may protect the ischaemic myocardium through redistribution of blood flow [ 181.
Theoretically, endothelin could protect the ischaemic myocardium through another mechanism. Ischaemic preconditioning, which is one of the most powerful means of protecting the myocardium during ischaemia and reperfusion, is probably mediated through stimulation of membrane receptors on cardiomyocytes which are coupled to an intracellular signal transduction pathway leading to the activation of protein kinase C [19] . Accordingly, protection by ischaemic preconditioning against infarction has been shown to be dependent on activation of protein kinase C in rabbit and rat hearts [19, 20] . Protection against infarction similar to that afforded by ischaemic preconditioning can be achieved by stimulation of a variety of membrane receptors all proposed to be connected to protein kinase C activation, including adenosine A, receptors [21] , a-adrenoceptors [22] , muscarinic M, receptors [23] , angiotensin AT, receptors [24] and bradykinin B, receptors [25] . In several cell systems, including the myocardium, stimulation of endothelin receptors also leads to protein kinase C activation [26] . Recently Wang et al. [27] reported that in the buffer-perfused rabbit heart stimulation of endothelin receptors prior to ischaemia could reduce infarct size through activation of protein kinase C. Also, Hide et al. [28] very recently reported that in the rabbit heart in vivo endothelin-1 could protect against infarction by activating ATP-sensitive potassium (KATP) channels.
Thus, the aim of the present study was to examine in the isolated rat heart if preischaemic treatment with endothelin-1 could cause protection against infarction similar to ischaemic preconditioning, and through which endothelin receptors a potential protection was mediated. The nonselective ETA/ET, receptor antagonist, bosentan [29] , and the specific ET, receptor antagonist, BQ-123 [30] , were used to study receptor involvement. The eventuality of protein kinase C involvement was examined by use of its inhibitor chelerythrine [3 11, while 5-hydroxydecanoate (5-HD) 1321 was used to examine whether activation of K ATP channels was involved. In the same model, we also examined if endothelin might play a role in mediating the anti-infarct effect of ischaemic preconditioning.
Methods

Perfusion procedure
The investigation conforms with the guidelines on accomodation and care of animals formulated by the European Convention for the protection of vertebrate animals used for experimental and other scientific purposes. Seventyseven Male Wistar rats (weight 250-320 g) fed a standard diet were heparinized with 200 IU and anesthetized with Na-pentobarbital 50 mg/kg intraperitoneally. The hearts were excised, placed in ice-cold buffer and rapidly mounted on the aortic cannula of a Langendorff perfusion system. Perfusion was established within 60 s after thoracotomy. The buffer (pH 7.4, oxygenated with 95% 0,/5% CO,) contained 11 mmol/l glucose and 2.4 mmol/l Ca*'. Perfusion pressure was maintained at 100 cmI-I,O, and the temperature was 37°C throughout each experiment. The hearts were perfused in the non-recirculating mode, except during the period when drugs were added to the buffer. A water-filled latex balloon, connected to a hydrostatic pressure transducer and coupled to a Gould recorder, was inserted into the left ventricle through an incision of the left atrium. Prior to insertion, the volume of the balloon was adjusted to assure that it was unstretched and thereafter left unchanged. Heart rate and left ventricular developed pressure were obtained as an average of the recorded values for 10 s at each sampling point. Coronary flow was measured by timed collection of effluent over 1 min at each sampling point. A 3-O silk thread was passed around the main branch of the left coronary artery, and the ends were threaded through a small vinyl tube to form a snare. Regional ischaemia was achieved by pulling the snare. Ischaemia was confirmed by a substantial fall in both left ventricular developed pressure and coronary flow.
Experimental protocol
The (experimental protocol used is shown in Fig. 1 . The time periods during which the various drugs were added to the perfusate are demonstrated in this figure. All hearts experienced an initial 20 min stabilization period before being subjected to 30 min of regional ischaemia and 120 min of reperfusion. Baseline values for functional parameters were obtained after 10 min of perfusion, before any drug addition. In the first part of the study, effects of endothelin-1 and of combinations of endothelin-1 and various inhibitors were studied. Eleven groups were included (n = 5-8 in each group). The hearts in the first group (Control) served as controls and were, after the stabilization period, subjected to 20 min of normal perfusion before regional ischaemia and reperfusion. The hearts in the second (ET 0.1 nM) and third (ET 1 nM) group were treated with endothelin-1 0.1 and 1 nM, respectively, for 3 X 5 min separated by 5 min of washout before the onset of regional ischaemia. The hearts in the fourth group (Flow reduced) were subjected to a progressively reduced coronary flow for 30 min prior to regional ischaemia. This flow reduction exactly followed the time course of the flow reduction caused by ET-l 1 nM, with a marked decrease during each of the three 5-min periods during which ET-l was infused and a small increase during the subsequent washout periods. Thus, the flow reduction was similar in magnitude and duration to the flow reduction caused by the highest endothelin-1 concentration (1 I&I). The hearts in the fifth group (ET + chelerythrine) were treated with endothelin-1 in the same concentration as the hearts in the third group (1 r&4), with addition of the protein kinase C inhibitor chelerythrine (2 PM). The hearts in the sixth group (ET + 5-HD) were treated with endothelin-1 combined with the K,, channel blocker 5-HD (100 FM), while the hearts in group 7 (Control + 5-m) were treated with 5-HD (100 PM) alone. In the eighth (ET + bosentan) and tenth group (ET + BQ-123), the hearts were treated with the same endothelin-I regime as in the ET 1 nM group, with addition of the nonselective ETA/ET, receptor antagonist, bosentan (1 PM), or the selective ET, receptor antagonist, BQ-123 (2pM), respectively. The hearts in groups 9 (Control + bosentan) and 11 (Control + BQ-123) were treated with the endothelin receptor blockers, bosentan (1 p.M), and BQ-123 (2 PM) alone, respectively. In the second part of the study we tested whether endothelin might play a role in the mechanism behind the anti-infarct effect of ischaemic preconditioning, and other two groups were included (groups 12 and 13). The hearts in the twelfth group (IF') were ischaemically preconditioned with three cycles of 5 min of global ischaemia + 5 min of reperfusion before the 30 min of regional ischaernia. In the thirteenth group (IP + bosentan), the ischaemic preconditioning protocol was combined with bosentan (1 PM).
Bosentan, BQ-123, chelerythrine and 5-I-ID were dissolved in saline and kept as stock solutions which were added to the perfusion buffer up to the final concentration immediately before use. Endothelin-1 was dissolved in the buffer immediately before use, and infused into the perfusion system just above the aortic cammla with a syringe pump (B. Braun Melsungen A.G., Germany) at an infusion rate of approximately 5% of the coronary flow.
The ischaemic preconditioning protocol with three cycles of occlusion and reperfusion was chosen because Liu and Downey [33] demonstrated that only one cycle did not protect the rat heart from infarction, while three cycles offered significant protection. The endothelin-1 protocol with three cycles of 5 min treatment separated by 5 min of washout was designed to match the ischaemic preconditioning protocol. Initial experiments showed that only one cycle of endothelin-I treatment did not protect against infarction in the present experimental model. Initial experiments also demonstrated that a higher endothelin-1 concentration of 10 nM caused very severe vasoconstriction and nearly abolished contractile function. Ischaemia-reperfusion experiments with this dose were therefore not included in the study. The concentration of chelerythrine was based on our earlier report [20] , while the concentration of 5-HD was based on the reported finding that 100 PM specifically blocked the anti-ischaemic actions of cromakalim, a K,, channel opener [32] . The concentration of bosentan was well above the reported IC,, [29] and completely abolished the endothelin-induced reduction in coronary flow. Similarly, the concentration of BQ-123 was well above the reported IC,, (301.
Measurement of ischaemic (risk) zone and infarct size
The measurement of risk zone and infarct size was carried out as described by Liu and Downey [33] . At the end of the experiment the silk snare was securely tightened and a 0.5% suspension of zinc-cadmium fluorescent particles (1 -10 p,rn in diameter) was infused into the petisate to mark the risk zone as non-fluorescent tissue. The hearts were weighed and frozen overnight before being cut into 2-mm-thick slices, thawed and stained by incubation at 37°C for 20 min in 1% triphenyl-tetrazolium-chloride in a phosphate buffer (pH 7.4). The slices were then immersed in 10% formalin to enhance the contrast of the stain, before being placed between two glass slides to a uniform 2 mm thickness. Area of the left ventricle, infarcted area (tetrazolium negative) and risk zone (non-fluorescent under UV-light) were traced on acetate, and the tracings were digitalized on a CalComp Drawing Board (CalComp, Anaheim, CA, USA). The areas were then determined by a computerized planimetry programme developed by E. Traasdahl (Department of Medical Physiology, University of Tromsca, Norway). Volumes of left ventricle, infarct zone and risk zone were calculated by multiplying each area by slice thickness and summing the products. Infarct size was expressed as a percentage of risk zone infarcted. Values are presented as mean it standard error of the mean (s.e.m.1. One-way analysis of variance combined with Tukey's test was used to test for group differences. Paired t-tests were used for within-group analyses to test for drug effects on hemodynamic parameters prior to ischemia. A P-value of less than 0.05 was considered significant. When doing multiple comparisons with t-tests, Bonferroni correction was employed.
Results
Infarct size
Risk zone volumes were not significantly different among the groups, mean risk zone volume being 356.6 f 8.4 mm'. Infarct size as a percent of the risk zone infarcted is shown in Figs. 2-4. Preischaemic treatment with endothelin-1 0.1 nM did not influence infarct size, being 40.9 f 3.0% (Fig. 1) . However, endothelin-1 1 nM significantly reduced infarct size from 41.9 + 3.4% in the control group to 14.1 j, 2.6% (P < 0.05, Fig. 2) . A preischaemic reduction in coronary flow similar in magnitude and duration to the flow reduction caused by the highest endothelin-1 dose resulted in a mean infarct size of 48.1 f 4.2%, which is not significantly different from the control group ( Fig. 2) . 130th th e nonselective ETJET, receptor antagonist, bosentan, and the ET, receptor selective antagonist, BQ-123, completely abolished the protective effect of endothelin-1. Infarct size in the ET + bosentan and ET + BQ-123 groups was 43.3 f 3.5 and 39.9 f 3.6%, respectively (P = n.s. vs. control group for both groups, Fig. 3) . None of the endothelin receptor blockers alone incluenced infarct six! in the control group. Infarct size in the Control + bosentan and Control + BQ-123 groups was 42.7 f 2.5 and 41.3 ,t .3%, respectively (Fig. 3) . The protein kinase C inhibitor, chelerythrine, completely abolished the anti-infarct effect of endothelin-1, infarct size in the ET + chelerythrine group being 41.1 f 5.2% (P = n.s. vs. control group, Fig. 3) . We have earlier shown that chelerythrine alone does not influence infarct size in this model [20] . Also, the K,,, channel blocker, 5-HD, completely
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abolished the protective effect of endothelin-1, infarct size in the ET + 5-HD group being 41.7 f 2.9% (P = n.s. vs. control group, Fig. 3 ). N-ID alone did not influence infarct size, as infarct size in the Control + S-I-ID group was 38.9 f 1.7% (P = n.s. vs. control group, Fig. 3 ).
Compared to the control group, ischaemic preconditioning significantly reduced infarct size to 6.1 f 1.4% (P < 0.05, Fig. 4 ). The nonselective endothelin receptor antagonist, bosentan, did not influence the protection caused by ischaemic preconditioning. Infarct size in the IP + bosentan group was 13.1 f 4.3% (Fig. 4). 
Functional variables
Coronary flow and left ventricular developed pressure during the experiments are shown in Tables 1 and 2, respectively. The baseline values for these parameters did not differ between any of the groups.
Infusion of the lowest dose of endothelin-1 (0.1 nM) led to a small but significant (P < 0.05) fall in coronary flow (Table 11 , but no significant changes in developed pressure ( Table 2 ). The highest dose of endothelin-1 (1 nM) led to a significant fall in both coronary flow (P < 0.05, Table 1 ) and left ventricular developed pressure (P < 0.05, Table  2 ). The effect of endothelin-1 1 nM on coronary flow is demonstrated in Fig. 5 . The hearts in group 4 were subjected to a flow reduction similar to that caused by endothelin-1 1 nM (Table 1, Fig. 51 , and a similar fall in developed pressure was observed ( Table 2 ). The nonselective endothelin receptor antagonist, bosentan, completely abolished the endothelin-1 -induced fall in both coronary flow (Table 1 ) and developed pressure ( Table 2 ). The ET, Baseline = at 10 mm of perfusion, before drug addition; Stabilization = at the end of the 20 mm stabilization period, which is 10 min after drug addition for chelerythtine, bosentan, BQ-123 and 5-HD treated groups; End ET = at the end of the last of the three 5-mm ET-infusions; Pre-ischaemia = immediately before the onset of regional ischaemia; 5' Ischaemia = at 5 mm of regional ischaemia; 120' Rp = at 120 mm of re.pe.rfusion. bP < 0.05 vs. corresponding stabilization value. 'P < 0.05 vs. control group at the same time point.
receptor selective antagonist, BQ-123, on the other hand, only partly blocked the endothelin-l-induced reduction in coronary flow (approximately 20% reduction compared to approximately 35% reduction in the endothelin-1 1 nM group, Table 1 ) and in developed pressure ( Table 2) . None of the endothelin receptor antagonists alone caused significant changes in coronary flow or left ventricular developed pressure. Chelerythrine, the protein kinase C inhibitor, caused an increase in coronary flow (P < 0.05, Table 11 , but did not influence the endothelin-l-induced fall in coronary flow (Table 1) or developed pressure ( Table 2 ). The blocker of K,,, channels, 5-HD, did not cause changes in coronary flow or developed pressure alone, and did not influence either the endothelin-1 induced fall in coronary flow or the fall in developed pressure. The ischaemic preconditioning protocol caused a small but significant increase in coronary flow (P < 0.05, Table 1 ) and a fall in developed pressure (P < 0.05, Table 2 ). Compared to the control group, left ventricular developed pressure immediately prior to the onset of regional ischaemia was significantly lower in the ET 1 nM group, the flow-reduced group, the ET + BQ-123 group, the ET + chelerythrine group, the ET + 5-HD group and the IP group (P < 0.05, Table 2 ). Occlusion of the coronary artery led to a substantial fall in both coronary flow (Table  1 ) and developed pressure (Table 2 ) in all groups; the former was immediately reversed upon reperfusion.
At the end of the experiments, the hearts in the flow-reduced group had a significantly lower left ventricular developed pressure than the hearts in the control group (P < 0.05). With this exception there were no significant differences in developed pressure between the ischaemitally preconditioned groups or between the nonpreconditioned groups at the end of the reperfusion period. Mean baseline heart rate for all groups was 283 f 3 beats/min (data not shown). None of the drugs used in the present study caused significant changes in heart rate. The only significant effect on heart rate seen was a fall from 303 + 16 at the end of the stabilization period to 224 f 8 (P < 0.05) at the end of the flow reduction protocol in the reduced-flow group. However, heart rate was not significantly different between the groups at any time point prior to ischaemia.
The baseline values for end-diastolic pressure were not different between any of the groups (data not shown), and did not differ between the groups throughout the experiments. hllean end-diastolic pressure for all groups was 2.9 f 0.2 mmHg at baseline, and 5.7 f. 0.5 mmHg at the end of the reperfusion period.
Discussion
The main finding of the present study is that preischaemic stimulation of endothelin receptors with endothelin-1 can lead to a pronounced reduction in infarct size in isolated rat hearts subjected to regional ischaemia and reperfusion. The protection was abolished by chelerythrine, which is reported to be a potent inhibitor of protein kinase C, and with a high specifity [31] . Recently, protein kinase C has been reported to activate K,, channels [34] , and in the present study the endothelin-l-induced protection was also abolished by 5-HD, a specific blocker of K *rp channels [32] . 5-HD did not influence infarct size alone, and we have earlier demonstrated that chelerythrine does not influence infarct size when added alone in the model used in the present study [20] . Thus, we have demonstrated that the protection was mediated through activation of protein kinase C and KATP channels. Our findings are in agreement with those of Wang et al. 12'7'1 who recently reported that in the isolated, buffer-perfused rabbit heart preischaemic activation of protein kinase C by endothelin-1 could limit infarct size to the same extent as ischaemic preconditioning. Our results also corroborate those of Hide et al., who recently demonstrated that, in the rabbit heart in vivo, infusion of endothelin-1 prior to ischaemia protected against infarction, an effect mediated through ATP-sensitive potassium channels [28] . The protective effect of endothelin-1 observed in the present study was abolished both by the nonselective ETJET, receptor antagonist, bosentan, and by the selective ET, receptor antagonist, BQ-123, thereby demonstrating that this effect of endothelin-1 is mediated through ET, receptors.
The finding that endothelin-1 actually can protect the ischaemic heart against infarction might seem contradictory to a number of reports that have demonstrated reduction of infarct size by inhibiting the actions of endothelin. In the anaesthetized rat [ill and rabbit [9] a monoclonal antibody against endothelin-1 has been reported to reduce infarct size, and reduced infarct size was also reported after blockade of ETJET, receptors during ischaemia and reperfusion in rat [ 131 and pig [ 123 hearts in vivo. In dog heart in vivo intracoronary infusion of BQ-123 during ischaemia and reperfusion also reduced infarct size [14] . However, several studies with infarct size as end-point have shown a lack of protective effect of endothelin receptor antagonists in vivo in rat [ 1.51, rabbit [ 171 and dog [ 161. Also, a recent study demonstrated that endothelin-1 can protect against infarction in the rabbit heart in vivo [28] . Thus, the protective effect of endothelin-1 demonstrated in the present study is not likely to be due to differences between the buffer-perfused heart model and the in vivo model. Speculatively, an explanation with respect to the diverging results could be that vasoconstrictor effects and effects on other organs than the heart appear as a confounding factor in some of the above-mentioned studies.
Protection against myocardial infarction has been reported after preischaemic stimulation of various membrane receptors which are all known to be coupled to an intracellular signalling pathway leading to activation of protein kinase C. This includes adenosine A, receptors [21, 33] , a-adrenoceptors [22] , angiotensin AT, receptors [24] , muscarinic M, receptors 1231 and bradykinin B, receptors [25, 35] . As the endothelin receptors on cardiomyocytes, like the receptors mentioned, are proposed to be linked to a protein-kinase-C-activating signalling pathway [26, 36] , it is in agreement with those findings that preischaemic stimulation of endothelin receptors can also limit infarct size.
In the present study, blockade of both ET, and ET, receptors with bosentan completely inhibited both the vasoconstrictory effect of endothelin-1 and the depressant effect on ventricular function, while blockade of ET, receptors with BQ-123 only partly inhibited these effects.
The protein kinase C inhibitor, chelerythrine, and the K,, channel blocker, 5-HD, did not influence these effects. All four agents, however, completely abolished the anti-infarct effect of endothelin-1. These results demonstrate that the anti-infarct effect of endothelin-1 is independent of its vasoconstrictory effects per se and thus probably independent of receptors in the vessel wall. This was further confirmed by the finding that a flow reduction prior to ischaemia similar in magnitude and duration to the flow reduction caused by the protective dose of endothelin-1 did not influence infarct size. The flow reduction to which the hearts in group 4 were subjected led to a significant fall in heart rate which was not seen in the endothelin-l-treated hearts. However, as heart rate was not significantly different between the groups prior to regional ischaemia, and as a reduction in heart rate should protect against ischaemic injury rather than aggravating it, the difference in effects on heart rate is unlikely to explain the difference in infarct size between these two groups. The finding that chelerythrine did not influence the effects of endothelin-1 on coronary flow demonstrates that the vasoconstrictory effect of endothelin-1 is mediated through an intracellular signalling pathway independent of protein kinase C, most likely through an increase in intracellular Ca" concentration mediated through inositol-3-phosphate (IPs) [37] .
Our findings indicate that the vasoconstrictory effects of endothelin-1 is mediated through both ET, and ET, receptors, and not through ET, receptors alone. This is in agreement with other reports from experiments in perfused rat hearts [38] and anaesthetized rats [39] , although it has been reported that endothelin-induced vasoconstriction is primarily mediated through ET, receptors [30, 40] . The dose of BQ-123 used in the present study is well above the reported IC,, of the drug for ET, receptors, which is in the nanomolar range [30] . The present dose of BQ-123 was also sufficient to abolish endothelin-1 's anti-infarct effect. The BQ-123 dose used was lOOO-fold greater than the dose of endothelin-1 (1 FM vs. 1 nM). We therefore believe that the ET, receptor was sufficiently blocked, and that in our model coronary vasoconstriction is mediated through both ET, and ET, receptors.
With respect to the mechanism behind ischaemic preconditioning against infarction, blockade of ET, and ET, receptors did not interfere with this protection. In rat [20] , as in rabbit [19] , activation of protein kinase C is a necessary step in the pathway leading to protection by ischaemic preconditioning. In rabbit [19] , swine [41] and dog [42] hearts stimulation of adenosine A, receptors seems to be the initial part of the signalling mechanism involved. In rat hearts, however, a similar role for adenosine receptors could not be demonstrated [33] . Also, oadrenoceptors [20] and bradykinin B, receptors [25] do not mediate the anti-infarct effect ischaemic preconditioning in the rat, although both adenosine [33] and bradykinin 125,431 are reported to afford protection against ischaemic injury in the rat heart. Stimulation of endothelin receptors is known to activate protein kinase C, endothelin is released ence was not significant. Also, global left ventricular from the perfused rat heart during ischaemia [4] , and both developed pressure is not the most sensitive parameter for ET, and ET, receptors are present on cardiac myocytes assessing ventricular function, and a more sensitive param- [44] . Thus, the possibility that endothelin released during eter for ventricular function (e.g., measuring regional venthe short preconditioning ischaemia might mediate the tricular function with ultrasonic crystals) would be needed anti-infarct effect of ischaemic preconditioning in rat hearts to allow c80nclusions with respect to effects of the various should be explored. However, the results of the present interventions on functional recovery. It could be argued study exclude this possibility in the isolated rat heart, and that, in the present study, the reduced infarct size in the it is still not known which membrane receptor(s), if any, endothelin-1 1 nM-treated hearts and the ischaemic premediates ischaemic preconditioning against infarction in conditioned hearts was due to reduced function at the onset the rat. K,,, channel activation is proposed to be the of regional ischaemia. However, the hearts in the reducedmechanism whereby ischaemic preconditioning protects flow group had large infarcts in spite of reduced preagainst myocardial infarction in some species, but this has ischaemic developed pressure. Also, the hearts treated with been difficult to prove in the rat [45] . In the present study endothelin-1 + chelerythrine, those treated with endotheendothelin-1 was demonstrated to protect against infarction lin-1 + MID and those treated with endothelin-1 + through activation of K,, channels. Thus, protection by BQ-123 showed large infarcts in spite of a similar reducendothelin-1 seems to be mediated by a mechanism sometion in pre-ischaemic mechanical function. This indicates what different from protection by ischaemic preconditionthat the reduction in infarct size is independent of preing in the rat, although protein kinase C seems to be a ischaemic function, which we have also earlier reported common factor. from experiments in the same model [20, 25] . While rabbits [19] can easily be preconditioned by only one cycle of ischaemia and reperfusion, a longer preconditioning protocol seemed to be needed in rat heart to allow a stable and reliable reduction in infarct size [33] . Apparently, the threshold for protection is higher in the rat. As discussed above, the initial stimulus for ischaemic preconditioning is different in the rat compared to rabbits. This difference could also count for the longer preconditioning protocol needed. Initial experiments showed that in the present study more than one cycle of endothelin infusion and washout was needed to achieve a stable reduction in infarct size. We recently made a similar finding with respect to protection against infarction by preischaemic stimulation of bradykinin B, receptors in the same model 1251. In the isolated rabbit heart, however, only one cycle of endothelin or bradykinin treatment and washout allowed for protection [27, 35] Thus, apparently the threshold for protection by preischaemic receptor stimulation as well is higher in the rat than other species. The explanation for this cannot be deduced from the present study. Speculatively, differences in receptor kinetics as well as different time periods needed for protein kinase C to be activated and/or for protein kinase C to phosphorylate the end-effector could be possible explanations.
In spite of the smaller infarcts in the endothelin-1 -treated hearts, functional recovery of the hearts treated with the protective dose of endothelin-1 was not significantly different from recovery for the control hearts. This demonstrates clearly that, in the present model, there is no relation between functional recovery and infarct size. This finding is also in agreement with other studies that have shown reduced post-ischaemic recovery of ventricular function after treatment with endothelin-1 [46] .
In conclusion, the present study has demonstrated that, in the isolated, buffer-perfused rat heart, pre-ischaemic treatment with endothelin-1 can limit infarct size through activation of protein kinase C and K,, channels, thereby in part sharing a common mechanism with ischaemic preconditioning. A role for endothelin-1 in mediating ischaemic preconditioning against infarction in the rat heart could, however, not be demonstrated.
